NOT FOR PUBLICATION
UNITED STATES COURT OF APPEALS FILED
FOR THE NINTH CIRCUIT JUN 23 2015
MOLLY C. DWYER, CLERK
U.S. COURT OF APPEALS
ARLEEN CABRAL, individually ) No. 13-55943
and on behalf of all others )
similarly situated, ) D.C. No. 5:12-CV-00085-MWF-OP
)
Plaintiff - Appellee, ) MEMORANDUM*
)
v. )
)
SUPPLE LLC, a Connecticut )
Corporation, )
)
Defendant - Appellant. )
)
Appeal from the United States District Court
for the Central District of California
Michael W. Fitzgerald, District Judge, Presiding
Argued and Submitted June 1, 2015
Pasadena, California
Before: FERNANDEZ and BEA, Circuit Judges, and MARQUEZ,** District Judge.
Supple, LLC appeals the district court’s order certifying a class of
purchasers of a dietary supplement sold by Supple in liquid and powder form (“the
*
This disposition is not appropriate for publication and is not precedent
except as provided by 9th Cir. R. 36-3.
**
The Honorable Rosemary Marquez, District Judge for the U.S. District
Court for the District of Arizona, sitting by designation.
Beverage”). We vacate and remand.
The Beverage contained glucosamine hydrochloride and chondroitin sulfate
as well as other ingredients, including vitamins and minerals. The certified class is
“[a]ll persons residing in the State of California who purchased [the Beverage] for
personal use and not for resale since December 2, 2007.” Cabral asserted that
Supple had made misrepresentations to herself and the other members of the class
in violation of a number of California statutes: California’s Unfair Competition
Law (“UCL”),1 California’s False Advertising Law (“FAL”),2 and California’s
Consumer Legal Remedies Act (“CLRA”).3 The district court determined that
Cabral had met the prerequisites for class certification4 as a class in which
“questions of law or fact common to class members predominate over any
questions affecting only individual members.”5 The district court declared that the
common issue which predominated was whether Supple had misrepresented to the
class members that “the Beverage is clinically proven effective in treating joint
1
Cal. Bus. & Prof. Code §§ 17200, 17203.
2
Cal. Bus. & Prof. Code § 17500.
3
Cal. Civ. Code § 1770.
4
See Fed. R. Civ. P. 23(a).
5
Id. 23(b)(3).
2
pain.”6 But in order for the issue to predominate, it must at least be common7 and
there must be cohesion among the class members.8 It is upon those rocks that the
district court’s certification founders.
In a case of this nature, one based upon alleged misrepresentations in
advertising and the like, it is critical that the misrepresentation in question be made
to all of the class members. See, e.g., Stearns, 655 F.3d at 1020; Mazza v. Am.
Honda Motor Co., 666 F.3d 581, 596 (9th Cir. 2012); Davis-Miller v. Auto. Club
of So. Cal., 201 Cal. App. 4th 106, 124–25, 134 Cal. Rptr. 3d 551, 565 (2011)
(CLRA and UCL); Fairbanks v. Farmers New World Life Ins. Co., 197 Cal. App.
4th 544, 562, 128 Cal. Rptr. 3d 888, 904 (2011) (UCL); Pfizer Inc. v. Super. Ct.,
182 Cal. App. 4th 622, 629–30 & n.4, 631–32, 105 Cal. Rptr. 3d 795, 801 & n.4,
802–04 (2010) (UCL and FAL claims); Cohen v. DIRECTV, Inc., 178 Cal. App.
4th 966, 980–81, 101 Cal. Rptr. 3d 37, 47–49 (2009) (UCL and CLRA). The
6
Cabral would have us expand the misrepresentation to a claim that the
Beverage has some efficacy, and Supple would have us narrow it by adding that
the pain must be caused by arthritis. We will do neither and will limit ourselves to
consideration of the issue actually identified by the district court.
7
See Wal-Mart Stores, Inc. v. Dukes, __ U.S. __, __, 131 S. Ct. 2541, 2556,
180 L. Ed. 2d 374 (2011).
8
See Amchem Prods., Inc. v. Windsor, 521 U.S. 591, 623, 117 S. Ct. 2231,
2249, 138 L. Ed. 2d 689 (1997); Stearns v. Ticketmaster Corp., 655 F.3d 1013,
1020 (9th Cir. 2011).
3
record in this case does not meet that standard; it will not support a determination
that all of the class members saw or otherwise received the misrepresentation that
the Beverage was “clinically proven effective in treating joint pain.” While some
deviations from precise wording in the language of advertisements or
representations might not be fatal to class certification,9 advertisements that did not
declare the Beverage to be “clinically proven effective in treating joint pain” are a
far cry from advertisements that did. It, therefore, cannot be said that the class was
properly certified. The district court abused its discretion,10 and we must vacate
the certification order.11
VACATED and REMANDED.
Costs awarded to Supple.
9
See Henry v. Lehman Commercial Paper, Inc. (In re First Alliance Mortg.
Co.), 471 F.3d 977, 990–91 (9th Cir. 2006).
10
See Berger v. Home Depot USA, Inc., 741 F.3d 1061, 1066–67 (9th Cir.
2014); see also United States v. Hinkson, 585 F.3d 1247, 1261–63 (9th Cir. 2009)
(en banc).
11
We express no opinion on whether a different class could be certified
regarding this controversy; we just decide that the district court erred in certifying
this class at this time. Similarly, we express no opinion on whether Supple’s
promotion of the Beverage was laudable or louche.
4